151 related articles for article (PubMed ID: 9795388)
1. Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes.
Kim JJ; Nottingham LK; Wilson DM; Bagarazzi ML; Tsai A; Morrison LD; Javadian A; Chalian AA; Agadjanyan MG; Weiner DB
Vaccine; 1998 Nov; 16(19):1828-35. PubMed ID: 9795388
[TBL] [Abstract][Full Text] [Related]
2. Functional equivalency of B7-1 and B7-2 for costimulating plasmid DNA vaccine-elicited CTL responses.
Santra S; Barouch DH; Jackson SS; Kuroda MJ; Schmitz JE; Lifton MA; Sharpe AH; Letvin NL
J Immunol; 2000 Dec; 165(12):6791-5. PubMed ID: 11120800
[TBL] [Abstract][Full Text] [Related]
3. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes.
Kim JJ; Bagarazzi ML; Trivedi N; Hu Y; Kazahaya K; Wilson DM; Ciccarelli R; Chattergoon MA; Dang K; Mahalingam S; Chalian AA; Agadjanyan MG; Boyer JD; Wang B; Weiner DB
Nat Biotechnol; 1997 Jul; 15(7):641-6. PubMed ID: 9219266
[TBL] [Abstract][Full Text] [Related]
4. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition.
Costello RT; Mallet F; Sainty D; Maraninchi D; Gastaut JA; Olive D
Eur J Immunol; 1998 Jan; 28(1):90-103. PubMed ID: 9485189
[TBL] [Abstract][Full Text] [Related]
5. The roles of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA.
Chan K; Lee DJ; Schubert A; Tang CM; Crain B; Schoenberger SP; Corr M
J Immunol; 2001 Mar; 166(5):3061-6. PubMed ID: 11207256
[TBL] [Abstract][Full Text] [Related]
6. Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination.
Vidalin O; Tanaka E; Spengler U; Trépo C; Inchauspé G
DNA Cell Biol; 1999 Aug; 18(8):611-21. PubMed ID: 10463057
[TBL] [Abstract][Full Text] [Related]
7. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens.
Kim JJ; Trivedi NN; Nottingham LK; Morrison L; Tsai A; Hu Y; Mahalingam S; Dang K; Ahn L; Doyle NK; Wilson DM; Chattergoon MA; Chalian AA; Boyer JD; Agadjanyan MG; Weiner DB
Eur J Immunol; 1998 Mar; 28(3):1089-103. PubMed ID: 9541605
[TBL] [Abstract][Full Text] [Related]
8. Costimulatory molecule immune enhancement in a plasmid vaccine model is regulated in part through the Ig constant-like domain of CD80/86.
Agadjanyan MG; Chattergoon MA; Holterman MJ; Monzavi-Karbassi B; Kim JJ; Dentchev T; Wilson D; Ayyavoo V; Montaner LJ; Kieber-Emmons T; Sekaly RP; Weiner DB
J Immunol; 2003 Oct; 171(8):4311-9. PubMed ID: 14530356
[TBL] [Abstract][Full Text] [Related]
9. Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.
Pettit SJ; Ali S; O'Flaherty E; Griffiths TR; Neal DE; Kirby JA
Clin Exp Immunol; 1999 Apr; 116(1):48-56. PubMed ID: 10209504
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of reduced T-cell effector functions and class-switched antibody responses to herpes simplex virus type 2 in the absence of B7 costimulation.
Thebeau LG; Morrison LA
J Virol; 2003 Feb; 77(4):2426-35. PubMed ID: 12551980
[TBL] [Abstract][Full Text] [Related]
11. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization.
Porgador A; Irvine KR; Iwasaki A; Barber BH; Restifo NP; Germain RN
J Exp Med; 1998 Sep; 188(6):1075-82. PubMed ID: 9743526
[TBL] [Abstract][Full Text] [Related]
12. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen.
Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
J Immunol; 2003 Mar; 170(6):2912-22. PubMed ID: 12626542
[TBL] [Abstract][Full Text] [Related]
13. Characterization of rat CD80 and CD86 by molecular cloning and mAb.
Maeda K; Sato T; Azuma M; Yagita H; Okumura K
Int Immunol; 1997 Jul; 9(7):993-1000. PubMed ID: 9237108
[TBL] [Abstract][Full Text] [Related]
14. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.
Bazhan SI; Belavin PA; Seregin SV; Danilyuk NK; Babkina IN; Karpenko LI; Nekrasova NA; Lebedev LR; Ignatyev GM; Agafonov AP; Poryvaeva VA; Aborneva IV; Ilyichev AA
Vaccine; 2004 Apr; 22(13-14):1672-82. PubMed ID: 15068850
[TBL] [Abstract][Full Text] [Related]
15. Differential requirements for expression of CD80/86 and CD40 on B cells for T-dependent antibody responses in vivo.
Lumsden JM; Williams JA; Hodes RJ
J Immunol; 2003 Jan; 170(2):781-7. PubMed ID: 12517941
[TBL] [Abstract][Full Text] [Related]
16. B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells.
Sojka DK; La Motte RN; Mokyr MB
Cancer Immunol Immunother; 2000 Apr; 49(1):10-22. PubMed ID: 10782862
[TBL] [Abstract][Full Text] [Related]
17. Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles.
Marsac D; Loirat D; Petit C; Schwartz O; Michel ML
J Virol; 2002 Aug; 76(15):7544-53. PubMed ID: 12097567
[TBL] [Abstract][Full Text] [Related]
18. In vivo CD86 blockade inhibits CD4+ T cell activation, whereas CD80 blockade potentiates CD8+ T cell activation and CTL effector function.
Lang TJ; Nguyen P; Peach R; Gause WC; Via CS
J Immunol; 2002 Apr; 168(8):3786-92. PubMed ID: 11937530
[TBL] [Abstract][Full Text] [Related]
19. Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo.
Kim JJ; Tsai A; Nottingham LK; Morrison L; Cunning DM; Oh J; Lee DJ; Dang K; Dentchev T; Chalian AA; Agadjanyan MG; Weiner DB
J Clin Invest; 1999 Mar; 103(6):869-77. PubMed ID: 10079108
[TBL] [Abstract][Full Text] [Related]
20. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes.
Ishioka GY; Fikes J; Hermanson G; Livingston B; Crimi C; Qin M; del Guercio MF; Oseroff C; Dahlberg C; Alexander J; Chesnut RW; Sette A
J Immunol; 1999 Apr; 162(7):3915-25. PubMed ID: 10201910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
